- Research works
- 20 ▼ 35% vs 2013–17
- Citations
- 453 22.4 per fractional work
- Top-10% rate
- 12.6% record average 16.5%
- Open access
- 37% world 28%
Not ranked overall: Kiadis Pharma (Netherlands) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Nursing, 39.2×. Every wedge is a field page.
Which keywords describe research at Kiadis Pharma (Netherlands)?
By fractional works in all years, weighted toward what it does more of than the world: Cancer Immunotherapy, CAR T Cells, Chimeric Antigen Receptor, Metabolic Syndrome, Hematopoietic Stem Cells, Early-Life Conditions, Fetal Programming and Mesenchymal Stem Cells.
- Nanoparticles
- NK Cell Recognition
- Genetic Variation
- Chiral Separation
- Bone Marrow Niche
- Mesenchymal Stem Cells
- Early-Life Conditions
- Metabolic Syndrome
- CAR T Cells
- Cancer Immunotherapy
- Chimeric Antigen Receptor
- Hematopoietic Stem Cells
- Fetal Programming
- Pharmacokinetics
- Graft-versus-Host Disease
- Drug Metabolism
- Liquid Chromatography
- Natural Killer Cells
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 18 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 18 words, with their numbers
- Cancer Immunotherapy2▲ 84×2 topics
- CAR T Cells2▲ 228×1 topic
- Chimeric Antigen Receptor2▲ 228×1 topic
- Metabolic Syndrome2▲ 9.7×2 topics
- Hematopoietic Stem Cells2▲ 79×2 topics
- Early-Life Conditions2▲ 116×1 topic
- Fetal Programming2▲ 116×1 topic
- Mesenchymal Stem Cells1▲ 56×2 topics
- Pharmacokinetics1▲ 24×2 topics
- Bone Marrow Niche1▲ 182×1 topic
- Graft-versus-Host Disease1▲ 182×1 topic
- Chiral Separation1▲ 45×1 topic
- Drug Metabolism1▲ 100×2 topics
- Genetic Variation1▲ 17×2 topics
- Liquid Chromatography1▲ 37×1 topic
- NK Cell Recognition1▲ 51×1 topic
- Natural Killer Cells1▲ 51×1 topic
- Nanoparticles1▲ 3.8×3 topics
Which research topics does Kiadis Pharma (Netherlands) publish most on?
By volume in 2022–2025: Birth, Development, and Health, Fatty Acid Research and Health, Autoimmune and Inflammatory Disorders Research and Immune Cell Function and Interaction.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Birth, Development, and Health Pediatrics, Perinatology and Child Health 2 works
- 2 Fatty Acid Research and Health Nutrition and Dietetics 0 works
- 3 Autoimmune and Inflammatory Disorders Research Hematology 0 works
- 4 Immune Cell Function and Interaction Immunology 0 works
- 5 CAR-T cell therapy research Oncology 0 works
- 6 Lipoproteins and Cardiovascular Health Surgery 0 works
- 7 Cancer, Lipids, and Metabolism Cancer Research 0 works
- 8 Diabetes, Cardiovascular Risks, and Lipoproteins Endocrinology, Diabetes and Metabolism 0 works
- 9 Atmospheric Ozone and Climate Atmospheric Science 0 works
- 10 Climate variability and models Global and Planetary Change 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Kiadis Pharma (Netherlands)'s research output changed?
Output in 2018–2022 was 35% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Duivendrecht
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.